CLIA technique is more sensitive that other immunological techniques, which is a great advantage in the rapid and accurate diagnosis of infectious diseases.

Clinically, patients with SARS-CoV-2 infection tend to suffer symptoms such as olfactory and gustatory dysfunction, fever, dry cough, ansomia, fatigue, dyspnoea, headache, diarrhoea and sore throat, followed by vascular and systematic complications. COVID-19 commonly results in pneumoia, which can evolve into acute respiratory distress syndrome, leading to respiratory or multiorgan failure.

On March 11, 2020, the WHO declared the disease a pandemic, due to the high number of infected people and the rapidity of tis spread worldwide.

CerTest CLIA SARS-CoV-2 particles are:

• High quality chemiluminescence reagents for both antigen and antibody detection.
• In-house controled development and production of antigens and antibodies.
• High level of production process control.
• CerTest Biotec knowledge in IVD test development.